CUE BIOPHARMA INC (CUE)

US22978P1066 - Common Stock

1.84  0 (0%)

After market: 1.84 0 (0%)

News Image
15 days ago - Chartmill

Wednesday's session: gap up and gap down stocks

These stocks are gapping in today's session

News Image
a month ago - Cue Biopharma, Inc.

Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

News Image
3 months ago - InvestorPlace

CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023

CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023.

News Image
3 months ago - BusinessInsider

CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cue Biopharma (NASDAQ:CUE) just reported results for the third quarter of 2023....

News Image
4 months ago - Cue Biopharma, Inc.

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T...

News Image
5 months ago - Cue Biopharma, Inc.

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023

Overall response rate (ORR) of 47% and disease control rate (DCR) of 65% in first line (1L) recurrent/metastatic HNSCC patients treated with CUE-101 and...

News Image
6 months ago - Cue Biopharma, Inc.

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

News Image
6 months ago - Cue Biopharma, Inc.

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Completed enrollment of patient expansion cohort of 20 patients at the RP2D of 4 mg/kg in combination with KEYTRUDA® (pembrolizumab) in first line (1L)...

News Image
8 months ago - Cue Biopharma, Inc.

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

News Image
9 months ago - InvestorPlace

3 Biotech Stocks to Buy as Companies Ink Major Deals

Pharmaceutical and biotech companies will soon face generic competition, creating big opportunity for these top biotech stocks to buy.

News Image
10 months ago - Cue Biopharma, Inc.

Cue Biopharma to Host Investor Call

News Image
10 months ago - Cue Biopharma, Inc.

Cue Biopharma to Host Investor Call

BOSTON, June 07, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

News Image
10 months ago - Cue Biopharma, Inc.

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

News Image
10 months ago - InvestorPlace

3 Biotech Stocks Sitting on Huge-Upside Catalysts

The biotech boom is hot. According to Grand View, it could be worth $2.44 trillion. It's why we have an eye on these top biotech stocks.

News Image
10 months ago - Cue Biopharma, Inc.

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

As of the data cutoff date, nine of the 14 evaluable patients treated with CUE-101+ KEYTRUDA® (pembrolizumab) demonstrated tumor regression, with five...

News Image
a year ago - Cue Biopharma, Inc.

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

News Image
a year ago - Cue Biopharma, Inc.

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

News Image
a year ago - InvestorPlace

7 Hot Growth Stocks Poised to Triple in 2023

These hot growth stocks to buy can triple in price in 2023, with some holding impressive upside that's much higher.